[Clinical trial of the antibacterial combination sulfamoxole/trimethoprim (CN 3123)/Fourth communication: Clinical results with CN 3123 in infections of the gastrointestinal tract, the skin and gynecological adnexes (author's transl)].
The antibacterial activity of N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) (CN 3123, Nevin, Supristol) was studied in various bacterial infections in the fields of internal medicine, dermatology and gynecology. It was found that: 1. CN 3123 exhibits antibacterial activity in bacterial infections of the intestinal tract, particularly in salmonellosis and shigellosis. 2. CN 3123 is effective against bacterial infections of the female genital organs. 3. CN 3123 is very effective in patients with bacterial infections of the skin. 4. The antibacterial activity of CN 3123 in these indications is comparable to its action on bacterial infections of the urinary organs and respiratory tract and in ENT infections.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002648:Child; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000292:Pelvic Inflammatory Disease / Q000188:drug therapy*; D012874:Skin Diseases, Infectious / Q000188:drug therapy*; D013423:Sulfamoxole / Q000627:therapeutic use*; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D014295:Trimethoprim; D013423:Sulfamoxole
Klinische Prüfung der antibakteriellen Kombination Sulfamoxol/Trimethoprim (CN 3123). 4. Mitteilung: Ergebnisse der klinischen Prüfung von CN 3123 bei Infektionen des Verdauungstraktes, der Haut und der gynäkologischen Adnexe